Pioneering the World's 1st Dark Matter Cancer Immunotherapy UbiVac's DPV-001 is the World's 1st Dark Matter Cancer Immunotherapy in the Cli ...

Two neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single ...

Understanding the symptoms, causes, and risk factors of esophageal cancer is important for early detection and prevention.

Researchers conducting a clinical trial of immunotherapy drugs for people with head and neck squamous cell carcinomas (HNSCCs ...

Some 7,000 people a year are diagnosed with work-related cancers, research on behalf of cancer charity KWF Kankerbestrijding ...

Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive ...

Head and neck squamous cell carcinomas responded better to a combination of two immunotherapies than to one immunotherapy ...

Researchers conducting a clinical trial of immunotherapy drugs for people with head and neck squamous cell carcinomas ...

Oesophageal cancer is a malignancy of the ... unresectable locally advanced esophageal squamous cell carcinoma and report a complete response rate of 42%.

Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...

The firm will assess whether adding its CD33-targeted radiotherapy Actimab-A to PD-1 inhibitors will benefit patients more than PD-1 inhibitors alone.

The combination of sintilimab and fruquintinib received conditional approval from China’s National Medical Products Administration (NMPA) for the treatment of patients with advanced endometrial cancer ...